VivoSim Labs (VIVS) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $0.16, -7.71% vs the prior close of $0.17.
- Volume 818.27K shares, 0.3x its 50-day average (light).
- New SEC filings: 8-K (Oct 16, 2026).
- No new insider buys or sales reported since the prior session.
VIVS slides 7.7% to $0.16, a 52-week low. Closed at $0.16, -7.71% vs the prior close of $0.17. Day range $0.15–$0.17, opened at $0.16.
VIVS daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — VIVS slides 7.7% to $0.16, a 52-week low
- Closed at $0.16, -7.71% vs the prior close of $0.17. Day range $0.15–$0.17, opened at $0.16.
- Volume was 818.27K shares, 0.3x its 50-day average of 3.08M — lighter than usual.
- Price is -39.2% vs its 50-day average ($0.26) and -86.5% vs its 200-day average ($1.17).
- 52-week range $0.15–$3.40; today's close sits at 0% of that range, 95.4% below the 52-week high.
Oct 15, 2026 — VIVS jumps 6.3% to $0.17
- Closed at $0.17, +6.25% vs the prior close of $0.16. Day range $0.15–$0.19, opened at $0.16.
- Volume was 3.51M shares, 1.2x its 50-day average of 3.03M.
- Price is -35.0% vs its 50-day average ($0.26) and -85.5% vs its 200-day average ($1.17).
- 52-week range $0.15–$3.40; today's close sits at 1% of that range, 95.0% below the 52-week high.
Oct 14, 2026 — VIVS slides 5.9% to $0.16, a 52-week low, 7 down days in a row
- Closed at $0.16, -5.88% vs the prior close of $0.17. Day range $0.16–$0.17, opened at $0.17.
- Volume was 356.60K shares, 0.1x its 50-day average of 3.09M — lighter than usual.
- Price is -39.7% vs its 50-day average ($0.27) and -86.5% vs its 200-day average ($1.18).
- 52-week range $0.16–$3.40; today's close sits at 0% of that range, 95.3% below the 52-week high.
- That makes 7 straight losses.
Oct 13, 2026 — VIVS ends flat (+0.0%) to $0.17, 6 down days in a row
- Closed at $0.17, +0.00% vs the prior close of $0.17. Day range $0.17–$0.18, opened at $0.18.
- Volume was 181.00K shares, 0.1x its 50-day average of 3.12M — lighter than usual.
- Price is -36.9% vs its 50-day average ($0.27) and -85.7% vs its 200-day average ($1.19).
- 52-week range $0.17–$3.40; today's close sits at 0% of that range, 95.0% below the 52-week high.
- That makes 6 straight losses.
Oct 12, 2026 — VIVS slides 5.6% to $0.17, a 52-week low, 5 down days in a row
- Closed at $0.17, -5.56% vs the prior close of $0.18. Day range $0.17–$0.18, opened at $0.18.
- Volume was 1.10M shares, 0.3x its 50-day average of 3.21M — lighter than usual.
- Price is -37.7% vs its 50-day average ($0.27) and -85.8% vs its 200-day average ($1.20).
- 52-week range $0.17–$3.41; today's close sits at 0% of that range, 95.0% below the 52-week high.
- That makes 5 straight losses.
Oct 9, 2026 — VIVS ends flat (+0.0%) to $0.18, 4 down days in a row
- Closed at $0.18, +0.00% vs the prior close of $0.18. Day range $0.17–$0.18, opened at $0.18.
- Volume was 332.20K shares, 0.1x its 50-day average of 3.32M — lighter than usual.
- Price is -34.8% vs its 50-day average ($0.28) and -85.1% vs its 200-day average ($1.21).
- 52-week range $0.17–$3.54; today's close sits at 0% of that range, 94.9% below the 52-week high.
- That makes 4 straight losses.
Oct 8, 2026 — VIVS slides 5.3% to $0.18, a 52-week low, 3 down days in a row
- Closed at $0.18, -5.26% vs the prior close of $0.19. Day range $0.17–$0.19, opened at $0.19.
- Volume was 872.70K shares, 0.3x its 50-day average of 3.32M — lighter than usual.
- Price is -35.8% vs its 50-day average ($0.28) and -85.2% vs its 200-day average ($1.22).
- 52-week range $0.17–$3.54; today's close sits at 0% of that range, 94.9% below the 52-week high.
- That makes 3 straight losses.
Oct 7, 2026 — VIVS slides 5.0% to $0.19, a 52-week low
- Closed at $0.19, -5.00% vs the prior close of $0.20. Day range $0.19–$0.21, opened at $0.20.
- Volume was 881.20K shares, 0.3x its 50-day average of 3.32M — lighter than usual.
- Price is -33.0% vs its 50-day average ($0.28) and -84.5% vs its 200-day average ($1.23).
- 52-week range $0.19–$3.54; today's close sits at 0% of that range, 94.6% below the 52-week high.
Oct 6, 2026 — VIVS slides 4.8% to $0.20
- Closed at $0.20, -4.76% vs the prior close of $0.21. Day range $0.20–$0.21, opened at $0.21.
- Volume was 374.90K shares, 0.1x its 50-day average of 3.34M — lighter than usual.
- Price is -30.4% vs its 50-day average ($0.29) and -83.8% vs its 200-day average ($1.24).
- 52-week range $0.19–$3.54; today's close sits at 0% of that range, 94.4% below the 52-week high.
- SEC filings that day: 8-K.
Oct 5, 2026 — VIVS jumps 5.0% to $0.21
- Closed at $0.21, +5.00% vs the prior close of $0.20. Day range $0.19–$0.21, opened at $0.20.
- Volume was 444.30K shares, 0.1x its 50-day average of 3.36M — lighter than usual.
- Price is -27.9% vs its 50-day average ($0.29) and -83.1% vs its 200-day average ($1.24).
- 52-week range $0.19–$3.54; today's close sits at 1% of that range, 94.1% below the 52-week high.
Oct 2, 2026 — VIVS slides 4.8% to $0.20
- Closed at $0.20, -4.76% vs the prior close of $0.21. Day range $0.19–$0.21, opened at $0.21.
- Volume was 804.50K shares, 0.2x its 50-day average of 3.36M — lighter than usual.
- Price is -32.3% vs its 50-day average ($0.30) and -84.0% vs its 200-day average ($1.25).
- 52-week range $0.19–$3.54; today's close sits at 0% of that range, 94.4% below the 52-week high.
VIVS latest news & SEC filings
Every SEC filing by or about VIVS in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 16, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
Oct 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
- Item 5.07 — Reported shareholder vote results.
Sep 1, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Lialin Tony Serge bought 10,000 shares at $0.28 (≈$2.80K) on Aug 31, 2026
- Lialin Tony Serge bought 10,000 shares at $0.28 (≈$2.80K) on Aug 31, 2026
- Lialin Tony Serge bought 10,000 shares at $0.28 (≈$2.80K) on Aug 31, 2026
- Lialin Tony Serge bought 10,000 shares at $0.28 (≈$2.80K) on Aug 31, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 21, 2026 · Form ARS — Annual report to shareholders
Annual report to shareholders
Aug 21, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 3.01 — Stock exchange listing notice or transfer of listing.
Aug 21, 2026 · Form DEF 14A — Proxy statement
Proxy statement — agenda for the shareholder meeting (board elections, executive pay, votes)
Aug 17, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 13, 2026 · Form PRER14A — PRER14A filing
PRER14A filing
Aug 12, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $18.00K (prior year $37.00K) (-51.4% vs Jun 30, 2025)
- Net income: -$1.34M (prior year -$2.84M) (loss narrowed vs Jun 30, 2025)
- Diluted EPS: -$0.25 (prior year -$1.14) (loss narrowed vs Jun 30, 2025)
Aug 10, 2026 · Form EFFECT — EFFECT filing
EFFECT filing
Aug 10, 2026 · Form PRE 14A — Preliminary proxy statement
Preliminary proxy statement
Aug 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 31, 2026 · Form S-1 — Registration statement (S-1)
Registration statement (S-1) — registering new shares, usually for an IPO or offering
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Jul 30, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.08 — Set shareholder nomination dates.
- Item 8.01 — Reported other events the company considers important.
Jul 24, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 3.01 — Stock exchange listing notice or transfer of listing.
- Item 8.01 — Reported other events the company considers important.
Things to know before you trade VIVS
- Last results release: Aug 6, 2026 (8-K Item 2.02). Previous ones: Apr 2, 2025, May 22, 2019, Feb 7, 2019. Based on that rhythm, the next report is likely around Nov 5, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 4.27% (largest 9.1%). That is a volatile stock.
- Liquidity: about 780.57K shares (≈$122.47K) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $0.16 vs a range of $0.15–$3.40 (0% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: 1:12 on Mar 21, 2025
- Insider trades (Form 4, last 12 months, recent 25 shown): 4 open-market buys, 4 sales; latest: Tony Serge Lialin bought 10,000 shares on Aug 31, 2026.
- Latest filings: 8-K Oct 16, 2026; 8-K Oct 6, 2026; 8-K Aug 21, 2026.
- Share count: 14.85M shares outstanding (Aug 10, 2026), +471.2% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
VIVS market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 0.16 | 0.17 | 0.15 | 0.16 | 818.27K |
| Oct 15, 2026 | 0.16 | 0.19 | 0.15 | 0.17 | 3.51M |
| Oct 14, 2026 | 0.17 | 0.17 | 0.16 | 0.16 | 356.60K |
| Oct 13, 2026 | 0.18 | 0.18 | 0.17 | 0.17 | 181.00K |
| Oct 12, 2026 | 0.18 | 0.18 | 0.17 | 0.17 | 1.10M |
| Oct 9, 2026 | 0.18 | 0.18 | 0.17 | 0.18 | 332.20K |
| Oct 8, 2026 | 0.19 | 0.19 | 0.17 | 0.18 | 872.70K |
| Oct 7, 2026 | 0.20 | 0.21 | 0.19 | 0.19 | 881.20K |
| Oct 6, 2026 | 0.21 | 0.21 | 0.20 | 0.20 | 374.90K |
| Oct 5, 2026 | 0.20 | 0.21 | 0.19 | 0.21 | 444.30K |
| Oct 2, 2026 | 0.21 | 0.21 | 0.19 | 0.20 | 804.50K |
| Oct 1, 2026 | 0.21 | 0.22 | 0.21 | 0.21 | 185.30K |
| Sep 30, 2026 | 0.20 | 0.22 | 0.20 | 0.21 | 558.10K |
| Sep 29, 2026 | 0.23 | 0.23 | 0.20 | 0.20 | 647.80K |
| Sep 28, 2026 | 0.23 | 0.23 | 0.22 | 0.22 | 423.90K |
| Sep 25, 2026 | 0.23 | 0.23 | 0.22 | 0.22 | 253.00K |
| Sep 24, 2026 | 0.23 | 0.23 | 0.22 | 0.23 | 559.00K |
| Sep 23, 2026 | 0.24 | 0.24 | 0.22 | 0.23 | 615.40K |
| Sep 22, 2026 | 0.25 | 0.26 | 0.23 | 0.24 | 1.24M |
| Sep 21, 2026 | 0.23 | 0.26 | 0.22 | 0.25 | 1.45M |
About VivoSim Labs
VivoSim Labs (VIVS) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in SAN DIEGO, CA. State of incorporation: DE. Fiscal year ends March 31. SEC CIK 1497253.
VIVS board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Douglas Jay Cohen | Director | Jan 29, 2026 |
| David Gobel | Director | Jan 29, 2026 |
| Alison Tjosvold Milhous | Director | Jan 29, 2026 |
| Keith Murphy | EXECUTIVE CHAIRMAN | Jan 29, 2026 |
| Adam K Stern | Director | Jan 29, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Tony Serge Lialin | Chief Commercial Officer | Sep 1, 2026 |
| Keith Murphy | EXECUTIVE CHAIRMAN | Jan 29, 2026 |
| Amar Akhtar Sethi | Chief Scientific Officer | Nov 26, 2025 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 31, 2026 | Tony Serge Lialin | Buy | 10,000 | $0.28 |
| Aug 31, 2026 | Tony Serge Lialin | Buy | 10,000 | $0.28 |
| Aug 31, 2026 | Tony Serge Lialin | Buy | 10,000 | $0.28 |
| Aug 31, 2026 | Tony Serge Lialin | Buy | 10,000 | $0.28 |
| Nov 17, 2025 | David Gobel | Sale | 3,266 | $2.24 |
| Nov 17, 2025 | David Gobel | Sale | 3,266 | $2.24 |
| Nov 17, 2025 | David Gobel | Sale | 3,266 | $2.24 |
| Nov 17, 2025 | David Gobel | Sale | 3,266 | $2.24 |
VIVS financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Mar 31, 2026 | $131.00K | $-13.84M | -5.35 | $-10.83M |
| Mar 31, 2025 | $144.00K | $-2.49M | -1.70 | $-9.46M |
| Mar 31, 2024 | $109.00K | $-14.67M | -19.25 | $-14.65M |
| Mar 31, 2023 | $370.00K | $-17.26M | -1.98 | $-12.41M |
| Mar 31, 2022 | $1.50M | $-11.45M | -1.32 | $-8.45M |
Latest balance sheet: total assets $3.85M, total liabilities $6.19M, cash $1.67M (as of Jun 30, 2026).
VIVS earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 6, 2026 | 8-K Item 2.02 (results) | $0.33 |
| Apr 2, 2025 | 8-K Item 2.02 (results) | $2.14 |
| May 22, 2019 | 8-K Item 2.02 (results) | — |
| Feb 7, 2019 | 8-K Item 2.02 (results) | — |
| Nov 8, 2018 | 8-K Item 2.02 (results) | — |
| Aug 9, 2018 | 8-K Item 2.02 (results) | — |
| May 31, 2018 | 8-K Item 2.02 (results) | — |
| Feb 8, 2018 | 8-K Item 2.02 (results) | — |
| Nov 9, 2017 | 8-K Item 2.02 (results) | — |
| Oct 4, 2017 | 8-K Item 2.02 (results) | — |
| Aug 9, 2017 | 8-K Item 2.02 (results) | — |
| Jun 7, 2017 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Revolution Medicines (RVMD)Argenx Se (ARGX)Kodiak Sciences (KOD)Greenland Mines (GRML)Halozyme Therapeutics (HALO)Biogen (BIIB)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on VIVS
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.